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ABSTRACT
CIRCULATING IMMUNE COMPLEXES IN SYSTEMIC LUPUS ERYTHEMATOSUS:
A SEARCH FOR THE ANTIGEN
Mark Stein
1984
In this study I have examined the composition of cryoprecipitates
obtained from the sera of patients with systemic lupus erythematosus
and normal donors and sought to determine whether these precipitates
contain immune complexes which have small nuclear ribonucleoprotein as
antigen component.

I found that the cryoprecipitable protein in serum

rapidly precipitated when sera were made to contain 3% polyethylene
glycol.

PEG fractions of normal sera and SLE sera were identical

except that the SLE precipitates contained greater amounts of
immunoglobulin G and IgM, and proteins with molecular weights between
80K and 60K, and 30K and 20K.

Double immunodiffusion demonstrated

that both normal and SLE sera contained IgM,
fibrinogen,

C2, C3 and C4, but

ceruloplasmin and C5 were not detected.

Using a DNA probe complementary to the U1 small RNA I searched
for snRNP immune complexes in SLE sera.

Sera was obtained from four

patients with SLE who were known to have anti-RNP or anti-Sm
antibodies (both antibodies precipitate the U1 small RNA) while their
disease was in its quiescent phase.

The U1 small RNA was not

detectable in immune complexes isolated from these patients.
These findings further expand our knowledge about the composition
of cryoglobulins and suggest that cryoprecipitation is due to the
increased concentration of one or more normal serum proteins.

The U1

ribonucleoprotein particle which is a major target for the autoimmune
response in SLE does not appear to participate in the formation of
circulating immune complexes.
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I.

ABBREVIATIONS USED

ANA
°C
CIg
cm
DNA
dsDNA
dsRNA
ENA
°F
g
hnRNA
hr
IgG,M,A,E
M
MCTD
mg
min
ml
mm
mRNA
MW
NBPC
PBS
PCA
Pg
RBC
RNA
RNP
rpm
rRNA
SDS
SLE
snRNP
ssDNA
ssRNA
yg
yi
V

V
WBC
w

antinuclear antibody
degree centrigade
cryoimmune globulin
centimeter
deoxyribonucleic acid
double stranded DNA
double stranded RNA
extractible nuclear antigen
degree Fahrenheit
gravity
heterogeneous nuclear RNA
hour
immunoglobulin G,M,A,E
molar
mixed connective tissue disease
milligram
minute
milliliter
millimeter
messenger RNA
molecular weight
nitrobenzyloxymethylpyridinium chloride
phosphate buffered saline
phenol-chloroform-isoamylalcohol
picograms
red blood cell
ribonucleic acid
ribonucleoprotein
rotations per minute
ribosomal RNA
sodium dodecyl sulphate
systemic lupus erythematosus
small nuclear RNP
single stranded DNA
single stranded RNA
micrograms
microliters
volume
volts
white blood cell
weight
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II.
A.

REVIEW OF LITERATURE
Introduction
Systemic lupus erythematosus (SLE) is a disease of unknown etiology

that is characterized by inflammatory lesions involving multiple organ
systems and multiple immunologic abnormalities (1,2).

SLE has a

prevalence of 1 per 1,000 population (3) and an incidence of 1
15,000 population (2).

in

It occurs three times more frequently in

blacks than in whites and is 10 times more common in females than in
males (4).

The peak age of onset is between 15 and 25 years.

The typical patient with SLE initially presents with fatigue
(95%),

fever (80%), arthralgia (90%) and a skin rash (15%) (1,4).

With the disease in its advanced stages the vital organs most often
involved are kidneys (55%),

lungs (45/6),

tract (40^) and the brain (30^) (1).

heart (45%),

gastrointestinal

Much of the tissue injury in SLE

results from the deposition of immune complexes.
When immune complexes are deposited, complement becomes
activated.
stimulated.

Phagocytic cells are attracted and phagocytosis is
Phagocytosis results in the release of lysosomal enzymes

and other cellular products which results in tissue injury.
complexes which form in SLE primarily involve autoantibodies.

The immune
Why the

immune system should lose tolerance to self antigens is not fully
understood but several explanations have been proposed.
cells downregulate the response of the immune system.

Normally, Ts
This loss of

tolerance may be due to the loss of suppressor T lymphocytes (5).
Several factors may lead to the loss of Ts cells.
case for a genetic component.

There is a strong

The HLA markers DRW2 and DRW3 are found

more frequently among SLE patients than the population at large (6).
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There is a 60$ concordance rate of SLE in identical twins (7).

SLE

patients have a higher incidence of other immune system disorders than
the population (8).

All these examples point to a genetically linked

cause.
A second possible cause for the autoimmune phenomenon is a viral
infection.

Viral nucleocapsids are frequently found in endothelial

cells of SLE patients.

Although no specific virus has been

implicated, antibody titers to various viruses are often elevated in
lupus sera.

Lastly,

several DNA and RNA viruses have been identified

which can induce a lupus like syndrome in laboratory animals (9,10).
B.

Antigens and Antibodies in SLE
In the sera of lupus patients,

autoantibodies have been found

against the cellular components listed below (11-13).

Clinically,

antigen-antibody complexes based on DNA are especially significant as
they are the type of immune complexes most often found in deposits
around basement membranes of the various organ systems (14).

It is

therefore thought that such complexes are responsible for much of the
pathogenesis of lupus and thus they have been studied extensively.
Antinuclear (including Extractible
Nuclear Antigen):

ssDNA
dsDNA
ssRNA
dsRNA
histones
Sm
RNP
La

Anticytoplasmic:

mitochondria
lysosomes
microsomes
ribosomes
rRNA
Ro

Anticell:

RBC
WBC
platelet

b

The first laboratory finding characteristic of SLE was reported
by Hargraves and colleagues at the Mayo Clinic (15).

They described

the appearance of swollen bodies in the cytoplasm of polymorphonuclear
leukocytes found in the bone marrow of a patient with SLE and called
these unusual polys "LE" cells.

The swollen bodies stained with

Feulgen reagent and so it was thought that they represented
phagocytized nuclei or nucleic acid.

By 1957 it was known that LE

cells could be experimentally produced by incubating damaged cells
with SLE serum containing polys.

Holman and Kunkel then showed that

by preincubating SLE serum with cell nuclei the serum loses its
ability to induce the formation of LE cells (16).

Furthermore,

when

slides containing LE cells were reacted with fluorescent rabbit
antiserum to human gammaglobulin the inclusion bodies of LE cells
fluoresced brilliantly.

From this evidence they correctly reasoned

that SLE serum contains antibodies directed against nuclear DNA.
the antibody-coated DNA is phagocytized by polys,

When

LE cells are formed.

The LE cell phenomenon thus became the first study of antinuclear
antibodies (ANAs).

Parallel work on different ANAs was performed in

the mid-fifties by Seligman and others (16-20).

These attempts

involved use of double immunodiffusion or fluorescent antibody
techniques to detect reactions between lupus sera and various cellular
components.

Most commonly, the antibodies reacted with DNA.

Unfortunately, these studies were criticized on the grounds that they
failed to differentiate between a reaction with naked DNA as opposed
to one with DNA associated proteins (21,22).

Later work overcame this

problem by showing that the reaction no longer took place if the
sample was first treated with DNase (22).

This showed that DNA
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comprised either the entire antigenic site or was a necessary
component of the antigenic site.
more sensitive and specific,

As immunochemical techniques became

the true nature of nuclear antigens came

to light.
There are essentially three types of anti-DNA antibodies;
which recognize ssDNA only,

those

those which recognize native DNA only and

those which recognize both ssDNA and nDNA (19,23-27).

Anti-ssDNA

antibodies react with determinants hidden in the native molecule.
Although the exact nature of the antigenic site is not known, Stollar
et al. believe that the antibodies are reacting with purine bases
(24,28).

They base this conclusion on the observation that purine

bases or the denatured end products of DNase digest inhibit the
binding of these antibodies to ssDNA.

Native DNA does not inhibit

this binding.
The second type of anti-DNA antibodies recognize determinants
common to both ssDNA and nDNA.

Again,

the exact nature of the

antigenic site is not known, but complement fixation studies indicate
that it is a small,

repeating unit —• possibly deoxyribose (23,26).

The third type of anti-DNA antibody binds exclusively to native DNA.
The antigenic site in this case is thought to be constituted by the
tertiary structural feature of the double helix (26).
researchers share this view.

Not all

They cite evidence which shows that

ssDNA, when present in high concentrations, inhibits the binding of
these antibodies to nDNA.

Others argue that this inhibition is due to

the recombination of two ssDNA chains.
Most of the early studies centered around DNA as the most
important reactive nuclear antigen.

This was partly due to the
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simplicity of isolation of DNA.
saline,
(29).

When nuclei are disrupted in isotonic

deoxyribonucleohistone is easily recovered as a precipitate
In his search for an SLE antigen other than DNA,

Holman

disrupted nuclei in saline,

discarded the precipitated DNA and

recovered the supernatant.

When this supernatant was saturated with

ethanol at room temperature a precipitate formed which,
acid,

bound to antibodies from SLE serum.

like nucleic

Since it was extracted from

the supernatant, Halman called it an extractible nuclear antigen
(ENA).

This ENA was found to be composed of acidic,

non-histone

proteins and RNA and so it is also called ribonucleoprotein (RNP)
(29).

Unlike DNA and nucleoprotein,

by DNase and trypsin.

RNP is insensitive to digestion

It is nondialyzable and is stable between pH's

5 and 9 and at temperatures less than 56°C.
discovery,

One year after Holman's

Tan and Kunkel described a second ENA (30).

The sera used

to detect this antigen came from a patient with the last name of Smith
and it was thus called Sm.

In addition to being resistant to DNase

and trypsin, Sm is also resistant to digestion by RNase.

Sm and RNP

are also referred to as small nuclear ribonucleoproteins (snRNP).
Each has a molecular weight less than 150,000 and a sedimentation
coefficient of 7S.

When bound to antibodies, each can fix complement

(29,30).
The molecular identity of the antigen recognized by anti-RNP and
anti-Sm antibodies finally became apparent when Lerner and Steitz
developed a new assay based on immunoprecipitation of extracts of ^2p
labeled HeLa cells.
cell's RNA.

In this assay 32P is first incorporated into the

The cells are then disrupted by sonication.

This

releases the labeled snRNPs and other molecules containing nucleic
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acids into the supernatant.

The snRNPs are bound to anti-Sm and anti-

RNP antibodies from SLE sera and the resulting immune complexes
precipitated with staphylococcal protein A.

Since snRNPs were thought

to be composed of RNA and protein, Lerner and Steitz examined these
components separately.
In their protocol,

the RNA part is recovered from the immune

complexes by extraction with phenol-chloroform.

The RNA is separated

on a urea-acrylamide gel and the location of these bands compared to
known RNA species (31).
which is called U1
labeled U1-U6.

Anti-RNP precipitated only one band of RNA

(see Figure 1).

Anti-Sm precipitated 5 bands,

These RNAs turned out to be a previously studied snRNA

species whose importance and function was not previously appreciated.
U1-U6 have since been fully sequenced and range in size from 100 to
200 bases.
To study the protein portion of snRNPs, HeLa cells were first
labeled with ^S-methionine.

35s is incorporated in all newly

synthesized proteins including the protein portion of snRNPs.

Again,

snRNPs are precipitated with SLE sera, adsorbed to a staph protein Asepharose column and then eluted from this column.
separates immune complexes from other proteins.

This procedure

The purified

complexes are then fractionated on an SDS-acrylamide gel.

It was found

that anti-Sm and anti-RNP antibodies can bind to the same seven
proteins.

The molecular weights of these proteins range from 12,000

to 35,000 Daltons.

Each snRNP contains only one snRNA species.

The

U1 snRNP complex is composed of the U1 snRNA and all seven proteins.
snRNPs containing the other U RNAs are composed of the respective RNA
and a subset of any five of the seven proteins (25,31,32).
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An intact snRNP complex is required for antigenicity.

Neither

anti-Sm nor anti-RNP can precipitate snRNAs after deproteinization.
Likewise, the protein portion of snRNPs cannot be precipitated after
the snRNA has been removed (33-35).
C.

Role of snRNPs
Although one gene codes for one polypeptide chain, many

eukaryotic genes occur in pieces.

Within the genome,

the

informational DNA sequences may be interrupted numerous times by
extraneous segments of DNA.

These intervening segments are known as

introns while the segments bearing information are called exons.

The

ends of an intron attached to the exon segments are called splice
junctions

The entire gene,

including both introns and exons,

initially transcribed to heterogenous nuclear RNA.
is then processed.

is

The hnRNA

The introns are cut out and the exons are spliced

together to form the final message.

Whereas the base sequence of

introns vary, the sequence of splice junctions is essentially
identical from gene to gene (36).
The mechanism involved in splicing is unknown.

Recently, Lerner,

Steitz and others proposed that snRNPs are intimately involved in this
process (37,38).

They reason that several conditions would have to be

met for their proposal to be valid.

From an evolutionary standpoint,

higher eukaryotic species possessing interchangeable transcription
systems should also possess the same splicing mechanism.

Therefore,

the structure of snRNPs should be highly conserved across different
species if they are to mediate splicing.

snRNPs from man,

frogs,

mouse, rat, chicken and sea urchins can all be precipitated by SLE
serum indicating that they are antigenically similar.

When sequenced,
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the snRNA from all these species are either highly similar or
completely identical to human snRNA (31,37,39,40).
Also, if the theory is correct metabolically active cells should
have a higher concentration of snRNPs than inactive cells.

In

relative terms, liver cells and erythroblasts can be considered
metabolically active and mature red blood cells inactive.

Studies

have shown that liver cells have a 25-fold increase in snRNPs over red
blood cells.

When the percent of the erythroblast component of blood

is increased the above ratio is decreased (37,41).
Further evidence for the theory could be found by showing that
removal of snRNPs blocks the splicing process and thus retards the
formation of mRNA.

Indeed, the addition of anti-Sm or anti-RNP

antibodies to a cell free splicing system will block the formation of
mRNA (42).

This shows that splicing is dependent on the presence of

snRNPs.
The most stringent condition that needs to be met is that snRNPs
should be able to recognize and bind to splice junctions since this
would be necessary to facilitate the splicing mechanism.
of both the 5’ and 3' ends of U1

The sequence

snRNAs are conserved and highly

complementary to the base sequence of splice junctions (37,38).

Thus,

the snRNP complex can both bind to splice junctions and participate in
the splicing mechanism.

Whether snRNPs serve only to align the

splice junctions or also to enzymatically cut out the introns is not
known.

The function of the other U snRNAs is not yet known but there

is growing evidence that they too are involved in the transcription
and translation processes (43).
Much less is known about two other ribonucleoproteins, La and Ro
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(44-46,79)*

Early cell fractionation and immunofluorescence studies

indicated that Ro and La were cytoplasmic in origin (45).

More recent

studies have demonstrated the antigenic identity of Ro to SS-A, and La
to SS-B.
cells,

SS-A and SS-B are two nuclear antigens extracted from Wi^

a lymphoblastoid cell line (44,47,49).

La is sensitive to

trypsin and both La and Ro are sensitive to ribonuclease.

They show

many physical similarities to Sm and RNP but do not contain the same
snRNA species (Figure 1).
D.

Significance of Antinuclear Antibodies
Antinuclear antibodies are often found in the serum of patients

with SLE and other rheumatic diseases.
individual,

While not present in every

nor found exclusively in any one disease,

certain ANAs are

thought to be characteristic of particular illnesses (Table 1).
Antibodies to ssDNA and dsDNA are found in 50-60% of all lupus
patients.

Those against histones and RNP are found in 25-40%.

Anti-

La is found in 10-15% and anti-Ro in 30-40% of SLE patients (27).
While Sm antibodies are present in only one third of SLE patients,
they are considered pathognomonic for lupus since they do not exist in
the sera of patients with other connective tissue diseases (48).
However, the most important point to consider is not the presence of
any one specific antibody,
present in lupus.

but rather the wide spectrum of ANAs

For example,

although anti-RNP is present in nearly

100% of patients with mixed connective tissue disease (MCTD), they are not
diagnostically significant since anti-RNP is also found in patients
with lupus and other rheumatic diseases.

What is important is that

the only other ANA present in MCTD is anti-ssDNA.

Therefore,

can be easily distinguished from MCTD because of the higher

lupus

variability of ANAs in the sera of lupus patients.
therefore,

Diagnostically,

the spectrum of antibodies can be more important than the

presence of a specific antibody.

One possible exception to this rule

is found in patients with neonatal lupus.

Nearly all infants and

their mothers have antibodies to only the Ro antigen (49-51).
The serum antigen or antibody concentration often correlates with
the severity of the disease.

For example,

recurrent bouts of very high fever,

in one patient with SLE,

skin rash and proteinuria

coincided with the appearance of DNA in his serum and resolved with
the appearance of anti-DNA antibodies (12).

High titers of anti-RNP

without elevation of anti-Sm is not predictive of the activity of SLE,
although it does correlate with the severity of MCTD (52-55).

The

presence of RNP antibodies in children with lupus is a poor prognostic
sign usually indicating renal and cardiac involvement and a high
fatality rate.

In MCTD, high titers of anti-Ro are associated with

polyarthralgia

(90$),

Raynaud's phenomenon

hypergammaglobulinemia (74$),
(73$),
(50$)

(81$),

polyarthritis (74$),

esophageal hypomotility (58$),

swollen hands

sclerodactyly (50$) and myositis

(56,57).
Research correlating Sm to the severity of SLE shows mixed

results.

Winn found that patients with Sm antibody and no DNA

antibodies have a milder form of lupus than patients who also possess
DNA antibodies (58,80).

In the latter group of patients,

hypertension, central nervous system disease and renal disease
occurred less frequently.

Specifically,

on renal biopsy only 1/23

patients with Sm antibodies alone had diffuse proliferative
glomerulonephritis whereas this was true for 6/14 patients who also
had DNA antibodies.

From this evidence it can be concluded that the
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level of antibody or antigen in a patient's serum often correlates to
the severity of a specific disease.
phenomenon have been mentioned;
E.

Some of the mechanisms for this

others have yet to be discovered.

The Property of Cryoprecipitability
In 1946 Lerner first described a group of proteins that

precipitated from cooled serum and named them cryoglobulins (59,60).
The major protein component of this mixture was separated and found to
have many physical properties similar to gamma-globulin.

Since that

time, cryoglobulinemia was found to be associated with many disease
processes.

Due to their immunochemical diversity, cryoglobulins have

been classified into three groups by Bonet et al.
composed of isolated monoclonal immunoglobulin:
or Bence-Jones protein.

(61).

Type I are

either IgM, IgG, IgA

Type II cryoglobulins are mixed cryoglobulins

with a monoclonal component possessing antibody activity against
polyclonal IgG.

Type III cryoglobulins are mixed polyclonal

immunoglobulins or nonimmunoglobulin molecules.

This last type of

cryoglobulin is predominantly present in inflammatory and autoimmune
diseases such as lupus erythematosus.
Many theories have been put forward to explain
cryoprecipitability.

Lerner originally hypothesized that this

property derived from modified gamma-globulins but could not determine
what the modification was (59).

His hypothesis represents the

classical theory of cryoprecipitation although it applies more to Type
I and II cryoglobulins than Type III.

Many researchers have expanded

on his theory.
Levo proposes that cryoprecipitation is due to immunoglobulins
which differ from normal by lacking sialic acid or other carbohydrate
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residues.

Removal of these residues leads to decreased solubility of

immunoglobulins.

Levo based his hypothesis on the results of chemical

analysis of immunoglobulin side chains obtained from the sera of
patients with cryoglobulinemia.
immunoglobulins:

Humans possess three kinds of

intracellular, membranous and secretory.

The

secretory kind is found in blood and differs from the intracellular
kind in the amount of carbohydrate residues that it possesses.
glycosylation is a post-transcriptional event (66,67).

This

Some secretory

immunoglobulin may leak out of B cells before glycosylation has had a
chance to take place.

This is evidenced by the fact that healthy

people contain small amounts of cryoprecipitable immunoglobulins in
their blood.

Infectious, malignant and autoimmune diseases are often

characterized by the intense stimulation of the lymphoreticular
system.

The glycosylation process may not be able to keep up with

this increased protein synthesis rate and so intracellular
immunoglobulins will leak out at a faster rate.

This, Levo

hypothesizes, causes the accompanying increase in cryoglobulin
formation.
A different explanation,

but one that is also based on the

decreased solubility of modified immunoglobulins, was proposed by
Erickson et al.

(68).

They feel that the modification lies in the

primary structure of the heavy chain variable regions of
immunoglobulins.

Point mutations cause different amino acids with

different side chains to be inserted in this region in place of the
normal amino acids.

These novel side chains when directed either

inwardly or outwardly, disturb the normal hydrophobic interactions and
change the folding pattern of adjacent segments of the protein.

The

immunoglobulin then assumes a configuration which is less soluble at
low temperatures.

They reached this conclusion by sequencing the

heavy chain variable regions of monoclonal immunoglobulins obtained
from two patients with cryoglobulinemia.

Both samples of

immunoglobulins contained extra residues in the outer beta sheet
structure of the

domain which on metric analysis were shown to

alter internal and external hydrophobic interactions.
Christian et al.

believe that the property of cryoprecipitability

is dependent on a heat labile serum factor (69).

In their study,

SLE

sera was first measured for its ability to form cryoprecipitates.

The

sera was then heated to 56°C and it was noted that this significantly
decreased the amount of precipitate which was later able to form.
The researchers concluded that a heat labile serum factor must play a
crucial role in initiating cryoprecipitation.

By adding back various

serum fractions, each enriched in one specific protein,

they identified

Cl and an 11s component of complement as two factors which could
restore cryoprecipitability.
Yet another protein which has been implicated in
cryoprecipitation is cold-insoluble globulin (CIg).

Although the identity

of CIg is not definitively known, its structure is believed to be a
two-chain dimer covalently bounded by disulfide bridges and folded
into a beta-structure (70-72).

CIg causes cryoprecipitation by

forming complexes with fibrin-fibrinogen.
temperature dependent;

These complexes are

forming in the cold and separating at body

temperature (73)
Some researchers feel that CIg is identical to the protein
fibronectin.

They base this conclusion on the observation that the
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two proteins have similar structures and are antigenically identical
(74).

Like CIg,

fibronectin also forms insoluble complexes with

fibrin-fibrinogen.

In recent studies linking fibronectin to

cryoprecipitation, fibronectin has been found in cryoprecipitates from
synovial fluid of five of five rheumatoid arthritis patients and from
the sera of two of two SLE patients (75,76).

In these studies,

removing fibronectin reduced the amount of cryoprecipitable material.
Hardin also suggests a model in which cryoprecipitability is a
property of large normal serum proteins and not of the immune
complexes themselves (77).

In one set of experiments,

normal non¬

immunoglobulin proteins were precipitated from normal sera with
polyethylene glycol.

These proteins had the property of precipitating

spontaneously at 4°C and resolubilizing at 37°C.

Experimentally

produced, cold soluble antigen-antibody complexes were made and mixed
with the cryoglobulins.

When incubated at 4°C,

the normal, cold

insoluble serum proteins were able to co-precipitate the immune
complexes.

Thus,

large serum proteins were shown to act as

cryoprecipitagogues, co-precipitating the immune complexes.

Another

line of evidence supporting non-immunoglobulin induced
cryoprecipitation is that sera from some patients can form
cryoprecipitates even though they do not contain any circulating
immune complexes as measured by the ^-’I-Clq binding assay (78).
Two explanations (which are not mutually exclusive) for
nonimmunoglobulin induced cryoprecipitation have been proposed.
first, as has been mentioned previously,

The

is that fibronectin binds to

cold-soluble fibrin-fibrinogen complexes to form cold-insoluble
complexes.

Fibronectin can be found in both PEG fractions of normal
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sera and in cryoglobulin isolated from patient serum (75-77).

The

second explanation is that cryoprecipitation is due to a normal
concentration effect.

In many disease states the serum concentration

of large proteins normally increases.

Intermolecular interactions

become more pronounced and this in turn leads to decreased solubility
in the cold.

Thus,

this theory is very simple and elegant in that it

does not call on special protein interactions or changes in protein
structure.
The non-immunoglobulin portion of cryoprecipitates has never been
systematically studied.

However, in the course of research done to

identify the mechanism of cryoprecipitation, a number of proteins have
been identified.

These are:

fibronectin (74-77),
fibrinogen (73).

Cl and 11s component of complement (69),

beta-|A and lipoprotein (61),

and fibrin and

It must be cautioned that not all of these proteins

were reported to be present by every investigator.
F.

Purpose of this Thesis
Two broad goals guided the work of this thesis.

My first

objective was to determine whether the sera of patients with SLE
contain immune complexes which have small nuclear ribonucleoprotein as
the antigen component.

As has been discussed, patients with lupus

produce antibodies which bind to specific snRNPs _in vitro.

The level

of these antibodies often correlates to the activity of the disease
and for this reason it is often clinically useful to monitor antisnRNP levels.

Likewise,

the presence of snRNP immune complexes may

also have prognostic and therapeutic implications.

As Tan and

colleagues pointed out, the onset of an acute flare in an SLE patient
was heralded by an increase in the DNA antigen whereas a remission was
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preceded by an increase in DNA immune complexes (12).

Since much of

the pathogenesis of SLE is due to the deposition of immune complexes
it may prove clinically important to ascertain the presence or absence
of snRNP immune complexes in various end organs.

Thus far the search

for these complexes has been hampered by the lack of a sensitive
technique with which to detect them.

Recently,

with the cloning of

the U1 gene and the development of hybridization techniques, a
powerful method for identifying the presence of snRNP immune complexes
has become available and has made the study of this problem possible.
My second goal was to examine the composition of cryoprecipitates
from normal and SLE sera.

Although cryoglobulins have been studied

extensively over the past 25 years, many fundamental questions remain.
We still do not fully know the composition of cryoprecipitates or
understand the mechanism for cryoprecipitation.
former may provide an answer to the latter.

Determining the

For example,

if it were

found that the only difference between cryoglobulins from lupus sera
and those from normal sera was an increase in the concentration of
immune complexes then this would support the theory that
cryoprecipitation is due to increased concentration of modified
immunoglobulins.

Likewise,

if it was found that the sole difference

was an increase in the concentration of normal serum proteins,
would support that mechanism of cryoprecipitation.

it

For these reasons

I identified some of the components of cryoglobulins by immunological
techniques and compared normal and lupus cryoprecipitates
electrophoretically.
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III.
A.

MATERIALS AND METHODS
Solutions

PBS
0.01M P04 (1.42gm/L)
0.15M NaCl (8.76gm/L)
pH 7.4
PEG (6% or 3%)
6gm of Polyethylene Glycol M.W. 6,000 in 100ml Borate Buffer
3gm of Polyethylene Glycol M.W. 6,000 in 100ml Borate Buffer
Borate Buffer
0.1M H3B03 (6.I8gm/L)
0.025M Na2B207*10H20 (9.53gm/L)
0.075M NaCl (4.38gm/L)
pH 8.3
Sucrose Solutions (10%, 40%, 60^)
lOgm, 40gm or 60gm of sucrose in 100ml of PBS
NET Buffer
50mM Tris (6.05gm/L)
150mM NaCl (8.7gm/L)
pH 7.5
NET-1
O.gm NP-40 in 100ml NET Buffer
NET-2
0.05gm NP-40 in 100ml NET Buffer
PCA
Phenol (redistilled) 50ml
Chloroform 50ml
Isoamylalcohol 1ml
8 Hydroxyquinoline 0.1gm
TBS
0.05M Tris-HCl (7.9gm/L)
0.150M NaCl (8.7gm/L)
pH 7.5
TBE
0.1M Tris (12.1Igm/L)
0.1M Borate (6.l8gm/L)
0.002M EDTA (0.74gm/L)
pH 8.3
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Sample Buffer for RNA Electrophoresis
7M Urea (420g/L)
0.1% Bromophenol Blue
0.1% Xylene Cyanol-FF
dissolved in TBE
Acetate Buffer
0.2M NaOAc (I6.4gm/L)
pH with 0.2M Acetic acid (12ml/L Glacial Acetic Acid)
pH 4.0
Solution for Stacker Part of Protein Gels
I. 6ml of 2M Tris-HCl pH 6.8
0.5ml of 0.2M EDTA
0.5ml of 10% SDS
34ml of H2O
9ml of 30% Acrylamide
0.05ml of TEMED
5ml of Ammonium Persulfate (0.38gm/25ml H^O)
Solution for Lower Part of Protein Gels
II. 88ml of 2M Tris-HCl pH 8.8
0.63ml of 0.2M EDTA
0.63ml of 10% SDS
24.38ml of H20
18.75ml of 30% Acrylamide
0.06ml of TEMED
6.25ml of Ammonium Persulfate (0.38gm/25ml H20)
Running Buffer for Protein Gels (Per 4L Solution)
Glycine I47gm
Tris 24.2gm
0.2M EDTA 40ml
10% SDS 40ml
pH 8.6
2X Sample Buffer for Protein Gels
61.5 yl of 2M Tris
400 yl of 10% SDS
100 yl of B-Mercaptoethanol
400 yl of Glycerol
10 yl of 0.5% B-cartoene dye
28.5 yl of H20
pH 6.8
10X NT
0.5M Tris-HCl (79gm/L)
0.5M MgCl
0.1M B-Mercaptoethanol
500 yg/ml BSA
pH 7.5
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Hybridization Buffer
50$ Formamide (500ml/L)
0.9M MaCl (52.6gm/L)
0.05M EDTA (1.86gm/L)
0.05M Na2HP04(7.1gm/L)
0.1$ SDS (Igm/L)
IX Denhardt's Solution:
0.02$ BSA
0.02$ Ficoll
0.02$ Polyvinylpyrrolidone
Salmon Sperm DNA (250 yg/ml),
pH 7.0

sonicated and denatured

B. Enzymes, Radionucleotides and Reagents
2'deoxyguanosine 5’triphosphate
2'deoxythymidine 5'triphosphate
32p_2* deoxyadenosine 5'triphosphate
^^P-2'deoxycytidine 5'triphosphate
DNA Polymerase I
DNAse
G25 Sephadex
Pansorbin
Minimal essential medium
Antisera against whole serum
IgG

cc43
fibrinogen
ceruloplasmin

New England Nuclear (NEN)
NEN
NEN
NEN
Boehringer Mannheim
Worthington
Pharmacia
Cal Biochem
GIBCO
Meloy
Meloy
Meloy
Meloy
Meloy
Meloy
Meloy

C. Human Subjects
5-50ml of blood was obtained from 6 patients and 12 controls
after obtaining informed consent.

The consent consisted of a full

explanation of the purpose for which the blood specimens will be used
and the potential risks of venipuncture.

All patients were followed

at the Yale Rheumatology Clinics and had systemic lupus erythematosus
as defined by the American Rheumatism Association (82).
D. Composition of Cryoprecipitates
1.

Preparation of Serum.

Approximately 100ml of blood was

obtained by venipuncture from patients and controls and allowed to
clot at 37°C for 30 min.,

followed by 30 min. at 4°C.

The clots were
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centrifuged at lOOOg for 10 min. at 4°C in an ICC clinical
centrifuge.

50ml of serum was recovered from each sample and

clarified further by re-centrifuging for 10 min.

Each was then

divided into two equal aliquots of 25ml (A^ and A2).
2.

Isolation of Cryoprecipitates.

incubated for 48 hr. at 4°C.

A^ aliquot serum was

The precipitate which formed was

sedimented at 12,000g for 10 min. at 4°C in a Sorvall RC-5B
centrifuge.

The pellet was washed 3 times with 10ml of PBS at 4°C.

The washing steps were carried out at 12,000g for 10 min. each.

The

thrice washed cryoprecipitate was re-solubilized in 1ml of PBS by
incubating for 30 min. at 37°C.
removed by centrifugation.

Any remaining insoluble material was

The cryoglobulins were allowed to re¬

precipitate at 4°C and were stored in this form (77).
3.

Isolation of Putative Cryoprecipitogogues.

carried out at 4°C unless otherwise noted.

All steps were

A2 serum was added to an

equal amount of 6% PEG in Borate buffer and incubated for 1 hr.

The

resulting suspension was sedimented at 12,000g for 10 min. and the
pellet washed with 3% PEG in Borate buffer.

The washed pellet was

solubilized in 1ml PBS by incubating for 30 min. at 37°C.
insoluble material was removed by centrifugation.

Any

The solution

(containing the putative cryoprecipitogogue) was dialyzed in 1cm
dialysis tubing for 24 hr. against 6 liters of PBS.

The resulting

precipitate was collected and stored in 1ml of PBS at 4°C (77,83).
4.

Electrophoresis of Cryoprecipitates.

Protein

electrophoresis was carried out using a modified O'Farrell technique
(86).

A 9% acrylamide pH 8.8 gel was used with a 5% acrylamide pH 6.8

stacker.

Gel dimension was 0.8 x 12 x 18cm.

Gels ran at 100V for
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4-6 hr. or at 50V overnight.

Sample buffer was prepared at 2X

concentration and mixed 1:1 (v/v) with the sample solution.

This

mixture was heated to 100°C for 1 min. before loading onto the gel.
After the run was finished, gels were stained with either Coomassie
Blue or "Silver Stain III" (87).
5.

Double Immunodiffusion.

Double immunodiffusion was performed

using a modified Ouchterlony and Tan and Kunkel method (30,88) (Figure
2).

agarose in PBS, with 0.1% sodium azide was layered 1mm thick

on glass microscope slides.
wells were punched out.

The agarose was allowed to harden and 6

10 y1 aliquots of solubilized cryoglobulins

were placed into wells in the outside ring.
specific antisera.

The center well contained

Diffusion was allowed to proceed for 24 hr. before

reading.
E.

Identification of snRNPs in Circulating Immune Complexes
1.

Detection of Immune Complexes.

Immune complexes in patient

sera were quantified by Dr. John Hardin using the ^5>I-C1q binding
assay (89).
2.

Isolation of Immune Complexes.

Immune complexes were

isolated by modification of the method previously described.

These

modifications were instituted to decrease the temperature and amount
of time required for isolation with the goal of decreasing the
degradation of RNA contained in the snRNP complexes by contaminating
RNase.

Briefly, blood was clotted for 30 min at 0°C.

The clot was

removed by centrifuging once at 1,000g for 10 min. at 0°C.

The serum

was added to an equal volume of 6% PEG in Borate buffer and slowly
stirred for 1/2 hr. at 0°C.

The precipitate was washed once with 3%

PEG and resuspended in PBS (v/10 starting volume)

(83).
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3.

Sucrose Density Gradients.

The suspension (1-2ml) was

layered on a 10%—40% linear sucrose density gradient with a 60%
sucrose base.

Nitrocellulose centrifuge tubes were used and the

sample spun at 27,000 rpm for 28 hr. at 4°C in a Beckman SW27 rotor.
At the end of each run,

gradient tubes were punctured from the bottom

and fractions collected dropwise (approximately 1ml per fraction).
The OD23Q of each fraction was automatically recorded with a Pharmacia
model UV-1 spectrophotometer which was connected in series with the
fraction collector.

The peak containing immune complexes was pooled

and used immediately in the next step (77).
4.

Extraction of RNA.

The pooled immune complexes were adsorbed

to Pansorbin, a commercial preparation of staphylococci protein A,
according to the method of Kessler (90).
at 0°C unless otherwise stated.

All steps were carried out

Briefly, 2ml of Pansorbin was

pelleted by centrifuging in a 10ml Corex tube at 7,000 rpm for 5 min.
in a SS34 rotor.

The pellet was washed once with NET-1 buffer and

twice with NET-2 buffer.
saved up to four days.

It was then resuspended in 2ml of NET-2 and

100 yl of washed Pansorbin was incubated with

the immune complex peak for 30 min.
adsorb the immune complexes.

This step allows protein A to

The suspension was washed five times

with NET-2 and resuspended in 400 yl of NET-2.

This was then mixed

with 400 yl of PCA in an Eppendorph tube and allowed to stand at room
temperature for 25 min.

The two-phase mixture was spun for 1 min. in

a Beckman B microfuge and the aqueous (top) phase removed and saved in
a new Eppendorph tube.

2 yl of carrier RNA (lOmg/ml) was added along

with 1.5ml of absolute ethanol.
1-2 hr.,

The tube was let stand at -20°C for

until all RNA precipitated.

The tube was then centrifuged
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for 5 min.,

the supernatant poured off and any remaining ethanol

lyophilized away.
5.

Preparation of known snRNP Immune Complexes.

isolated from HeLa cells and incubated with anti-Ro,
Sm antisera (3D.
noted.

snRNPs were
anti-La and anti-

All steps were performed at 0°C unless otherwise

HeLa cells were grown in minimal essential medium to a

concentration of 4 x 10^ cells/ml.
2,000 rpm for 5 min.

100ml of cells were sedimented at

in a SS34 rotor and the supernatant discarded.

The pellet was washed with 10ml of TBS and then resuspended in 2ml of
TBS.

The cells were broken by sonication for 3 x 30 sec. at setting 3

of a Branson sonifier.

The suspension was clarified by centrifugation

at 8,000 rpm for 10 min. and the supernatant retained as the source of
antigen.

100 yl of

antigen was incubated in an Eppendorph tube for

15 min. with 20 yl of known antisera kindly provided by Dr. John
Hardin.

On completion of the incubation step,

100 yl of washed

Pansorbin was added and the RNA isolated as described in part 4.
6.

Electrophoresis of RNA.

RNA from immune complexes and

control RNA were dissolved in 30 yl of sample buffer.

The samples

were heated at 60°C for 5 min. to denature the RNA and then loaded
onto the gel (31).

In addition,

^2p labeled RNA standards,

kindly

provided by Dr. Joan Steitz,

were run as controls to ensure proper

transfer to Northern paper.

The gel was 0.8 x 10 x 13cm and 10%

acrylamide-4M urea.

It was run at 300V for approximately 4 hr. (until

the second dye was about to run off).
buffer.

TBE was used as the running

Following completion of electrophoresis the gel was washed

3 x 20 min. with acetate buffer (31).
7.

Northern Transfer.

The Northern procedure allows
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electrophoretically separated nucleic acids to be covalently bound to
cellulose paper (91).
hybridization.

The paper-RNA is used as a solid support for

All steps were carried out in a hood.

Whatman 540

filter paper was cut to 10 x 12cm size and treated with a solution of
NBPC and sodium acetate (2.3mg nitrobenzyloxymethyl pyridinium
chloride and 0.7mg sodium acetate in 28.5 yl of water per square
centimeter of paper) at 60°C for 3-5 min. or until the paper
nominally dry.

was

The paper was then more fully dried in a 65°C oven for

20 min. and then at 135°C for 40 min.

It was then washed four times

with distilled water and three times with acetone.

These steps result

in the covalent linkage of n-nitrobenzyl groups to the cellulose.

The

paper was then incubated at 60°C for 30 min. in 150ml of 20$ (w/v)
sodium dithionite.

It is then washed with water and 30$ acetic acid.

These steps result in the reduction of the nitro group to an analine
group.

The paper is incubated for 1/2 hr.

in ice cold 1.2M HC1

(0.3ml/cm ) and sodium nitrate solution (2.7ml of lOmg/ml NaN02
solution per 100ml of HC1 used).

This converts the analine group

into a diazo group that can covalently bind RNA.
is similar to Southern's.
temperature (Figure 3)
8.

The transfer itself

Transfer is carried out overnight at room

(91).

Preparation of Radioactive Probe.

Plasmid DNA containing the

U1-RNA gene was kindly provided by Dr. Alan Weiner.

1 yl of DNA (0.4

yg/ yl) is added to an Eppendorph tube containing 2.5 y 1 of 10X NT
buffer and 2.5 yl of two nucleotides (10 yM),

usually

2'deoxyguanosine 5'triphosphate and 2'deoxythymidine 5'triphosphate.
1 yl DNAse (lOOpg freshly diluted from 1 mg/ml) is added and the
mixture incubated at 25°C for 10 min.

(47,92).

The DNAse creates
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numerous nicks in the plasmid.

7 yl of ^^P-2'deoxycytidine 5'-

triphosphate and 2.5 yl (10 units) of DNA polymerase I are added and
the mixture incubated at 15°C for 1 hr.

In this step,

the polymerase

incorporates the hot and cold nucleotides in the spaces where nicks
were previously created.

The reaction is stopped by passing the

mixture over a 3ml G25 Sephadex column equilibrated with 10mM Tris, pH
7.0.

The first peak contains the radioactive probe which is then used

for hybridization.

0.5ml fractions were collected from which 5 yl

aliquots were withdrawn and tested for radioactivity in a Packard 3385
scintillation counter.
9.

Hybridization.

The Northern paper which is now covalently

bound to the electrophoretically separated RNA is incubated with 15ml
of hybridization buffer plus 1 % glycine at 42°C for 48 hr.
this time,

the hybridization vessel is constantly,

After hybridization,

During

gently agitated.

the paper is washed 2 x 15 min. with 250ml of 2X

SSC buffer plus 0.1$ SDS, and then 2x15 rain, with 250ml of 0.2X SSC
plus 0.1$ SDS at 45°C (91).
The paper is blotted dry,

covered with Saran Wrap and placed on

top of Kodak XRP-1 X-ray film.

The film is exposed for 48-96 hr. at

-70°C.
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IV.
A.

RESULTS
Composition of Cryoprecipitates
1.

Comparison of Cryoglobulins to PEG Precipitates.

Cryoglobulins are serum proteins that precipitate at low temperature.
Often, only very little precipitate is obtainable from normal serum.
PEG is known to precipitate immune complexes as well as large amounts
of other reversibly cryoprcipitable proteins (77,83).

Since a large

supply of cryoglobulins is not easily available, it would be helpful
to know if PEG cuts could be used as a substitute.

For this reason

the protein composition of PEG cuts was compared to cryoglobulins
obtained by precipitating in the cold.
Normal volunteers donated 100ml of blood each,
serum was obtained.

from which 50ml of

The sera were divided into two fractions;

one

treated with PEG and the other left at 4°C to allow cryoglobulin to
precipitate.

Three sets of cryoglobulins and three PEG cuts were

loaded into separate wells in an acrylamie gel (84,85).
containing five standard proteins of MW 94K,

67K,

a lane containing IgG and IgM were also included.
the run,

the gels were stained and photographed.

43K,

A lane
30K and 20K and

After completion of
A total of 20 bands

were visualized in each of the cryoglobulin and PEG lanes.
these bands clearly corresponded to IgG and IgM.

Two of

Each band from the

cryoglobulin samples matched up with a corresponding band from the PEG
samples.

This experiment demonstrates that cryoglobulins and PEG cuts

of sera are identical in their protein composition (Figure 4).
The above experiment was repeated, only this time using serum
from patients with SLE.

Again, 20 bands were visualized and there

were no differences noted between the PEG fraction and the cold
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precipitated fractions.
2.
Sera.

Differences between Cryoprecipitates from Normal Sera and SLE
The differences in cryoprecipitates between normal and SLE sera

is of great importance.

This information will increase our knowledge

of the mechanism of cryoprecipitation and aid our understanding of the
pathophysiology of lupus.

In the first set of experiments,

cryoglobulins from SLE and normal sera were compared
electrophoretically (84,85).

1ml of serum was obtained from four SLE

patients and four healthy controls.

Cryoglobulins were precipitated

with PEG and each sample loaded onto an acrylamide gel along with a
mixture of five standard proteins.

After running for the appropriate

time,

the gel was stained with Coomassie Blue or Silver Stain III

(86).

As in the previous experiment,

lane.

The SLE lanes were identical to the normal cryoglobulin lanes

in their protein composition.

20 bands were visualized in each

Each protein band from the patient

samples had a matching counterpart in the control lanes.

The protein

concentration of these samples were, however, markedly different.
Essentially, there was a generalized increase in concentration of
proteins from the SLE samples.

Specifically, proteins with MW between

80K and 67K, and 30K and 20K were most markedly increased in
concentration (Figure 5).

This evidence gives further support to the

theory that cryoprecipitation may be due solely to a concentration
effect.
Type III cryoglobulins contain polyclonal immunoglobulins as well
as numerous serum proteins.

Some of these proteins have been

identified although the majority remain unknown.

In order to

establish the identity of new proteins and confirm previous findings,

2S

double immunodiffusion on Ouchterlony plates was performed (30,87).
1,6 agarose was used and the diffusion allowed to proceed for 24
hours.

Cryoglobulins were obtained from the sera of six patients and

eight controls and tested against antisera to the following:
C^,

fibrinogen,

ceruloplasmin, IgG and whole serum.

C^,

C^,

As expected,

antisera against IgG and whole serum showed very strong reactions.
and

antisera each precipitated a line of identity with

cryoglobulins from four of six patients and five of seven controls.
showed only a weak reaction with one patient and no controls.
Fibrinogen and ceruloplasmin did not precipitate lines of identity
with any sera (Table 2).
B.

Absence of Circulating snRNP Immune Complexes from Sera of Four
Patients with SLE.
Lupus patients often possess antibodies against two extractible

nuclear antigens,

Sm and RNP (31).

The molecular identity of their

RNA has been established as the nucleoplasmic snRNA species U1
and U1,

U2,

U4-6 (Sm) (31).

(RNP)

Although antibodies to these snRNPs have

been found in SLE sera, intact immune complexes have never been
identified.

Recently, with the cloning of the U1 gene a powerful

technique to identify the presence of snRNP complexes has become
available.
Four patients with SLE donated 50ml of blood from which 25ml of
serum was recovered.

All patients were previously found to possess

antibodies against Sm or RNP or both.

Cryoglobulins were precipitated

with 6% PEG and loaded onto a 10-40^ sucrose density gradient.
completion of the run,

After

the gradient was fractionated and each fraction

tested spectrophotometrically for its protein content.

Three peaks
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were identified (Figures 6,

7).

represents sedimented debris.

The first peak (bottom of gradient)
The second is found at the 19S level

and represents free serum proteins (77).

Fractions representing the

second peak were pooled and adsorbed to Pansorbin.

Any RNA that was

present was extracted with PCA and loaded onto a urea-acrylamide gel.
Control snRNP immune complexes were prepared and the RNA extracted as
described with the experimental samples.
standards were also loaded.
transfer procedure,

Likewise, ^2p iabeied RNA

After completion of the gel run and

the Northern paper was hybridized with the U1

probe.
An autoradiograph visualizes lanes 5,

6 and 7 (Figure 8).

Lanes

5 and 6 represent control immune complexes and signify three things.
The first is that RNA could not have been lost or somehow degraded
during the extraction steps.

The second is that the transfer

procedure was performed properly.

The fact that the radiolabeled RNA

standards located in lane 7 are also visualized serves as a second
control for this step.

Lastly,

visualizing a band in lanes 5 and 6

indicates that hybridization must have taken place.
explain these findings.

Three reasons can

The first is that the method used is not

sensitive enough to visualize naturally occurring immune complexes.
This explanation is unlikely since the Northern procedure can
visualize as little as lOpg of RNA per band.

The second reason is

that the RNA in the complexes was degraded by ribonucleases (29,30).
This is also unlikely since Sm is resistant to RNases and the
isolation procedure was carried out rapidly and at low temperature.
The third possibility is that circulating snRNP immune complexes are
not present _in vivo.
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DISCUSSION
A.

Composition of Cryoprecipitates
In 1973, Creighton et al. reported that immune complexes can be

precipitated by polyethylene glycol (83).

Recently,

Hardin described

a group of reversibly cryoprecipitable non-immunoglobulin proteins
which precipitate from normal sera treated with

3% PEG (77).

Considered together, these immune complexes and serum proteins
resemble the cryoglobulins first described by Lerner (59,60).
This work found that a PEG cut of normal serum is
electrophoretically identical in its protein composition to
cryoglobulins precipitated in the cold.

For the proteins tested,

two samples are also immunologically identical.

the

Studies of

cryoglobulins can thus be carried out using PEG cuts rather than
proteins precipitated in the cold.

One immediate benefit is the

reduction in time needed to perform the isolation steps from three
days to just a few hours.

Using PEG cuts will allow experiments to be

run which were previously difficult and costly to perform.

Large

quantities of serum are required to obtain usable amounts of protein,
even from SLE patients who have relatively large quantities of
cryoglobulins.

PEG causes nearly complete precipitation so even a

small amount of serum provides sufficient amounts of cryoprecipitates.
When cryoglobulins from normal and lupus patients were
electrophoretically compared,

the band pattern showed that the protein

composition of the samples is identical.

The only noted difference

was an increased concentration of proteins in the lupus samples.

This

result sheds some light on the mechanism of cryoprecipitation in SLE.
First,

it essentially rules out the possibility of disease specific
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proteins as a cause of cryoglobulinemia.
visualized in the SLE samples,

Since no new bands were

cryoprecipitation must be due to the

increased concentration of one or more proteins normally present in
the serum.

Although immunoglobulin was one of the components found

increased in concentration, it is unlikely that it is the predominant
cause of increased precipitation.

As Hardin and others have pointed

out cryoprecipitation can occur in serum deficient in immune complexes
(77,78).

Also, removing immune complexes from PEG cuts does not

eliminate the reversible cryoprecipitability of the remaining
proteins.

Thus,

Levo's, Erickson's and Christian's theories on

cryoprecipitability do not apply to SLE (62-64,68,69).
two likely causes of cryoprecipitation.

There remain

The most likely candidate for

a normal protein causing cryoprecipitation is fibronectin.
Fibronectin reversibly binds fibrinogen in the cold to form complexes
around which other proteins precipitate.

Its removal from sera

significantly decreases the amount of precipitate that will form (7577).

The other explanation is that cryoprecipitation is due to normal

molecular interactions of proteins in a saturated solution resulting
in precipitation in the cold.

These two explanations are not mutually

exclusive and most likely act in concert.

Hopefully,

future

experiments will show the relative contribution of each mechanism.
Although cryoprecipitation can occur without immune complexes
being present,

that cryoglobulinemia is intimately linked to an

aberrant immune response is undeniable.
surprising that this study found C^,
in cryoprecipitates.

Consequently,
and possibly

it is not
to be present

This evidence further extends our knowledge

about the protein identity of cryoprecipitates.

Future experiments may
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want to determine the location of the various proteins in an
acrylamide gel by using radiolabeled antisera.

This would

unambiguously identify which proteins are increased in concentration
in lupus sera and thus further elucidate the mechanism of
cryoprecipitation.
B.

Absence of Circulating snRNP Immune Complexes from Sera of Four
Patients with SLE.
As mentioned previously,

lupus patients have antibodies which

bind to snRNPs jin vitro and so are also thought to have the complexes
in vivo.

In the last part of this work,

we set out to identify

circulating snRNP immune complexes in the blood of lupus patients.
The hybridization technique used is very sensitive and can detect less
than lOpg of RNA per band (91).

Controls were used at each step and

were positive throughout.
snRNP complexes were not visualized.
do not exist _in vivo.
antibodies.

One explanation is that they

SLE patients produce a broad spectrum of

Although each is targeted against one particular antigen,

they may cross react with an unrelated though antigenically similar
compound.

Thus, snRNPs may not be the in vivo target of these

antibodies but rather represent a cross reaction jji vitro.

However,

this can only be proven by exclusion (by ruling out all other
explanations) or by finding another antigen in lupus sera which also
reacts with the same antibodies.
A second explanation is that the techniques used were not
sensitive enough to detect the immune complexes.

In light of the

sensitivity and specificity of the techniques used, this seems
unlikely.

However, it may be that while antibodies to snRNPs are

34

always present in the sera of some patients with SLE, the immune
complexes themselves are only present during an acute phase of the
disease.

Once a patient gets over the acute phase,

complexes may be quickly cleared from the blood.

the immune

Since blood samples

were obtained during a quiescent phase, this may explain why no
complexes were found.
A third explanation is that RNA portion of the snRNPs was
degraded by ribonucleases during the isolation steps.

This is also

unlikely since all steps were carried out rapidly and at either 0°C or
4°C.

Furthermore,

snRNPs are relatively insensitive to attack by

ribonucleases (29,30,47).

The last explanation is that the immune

complexes were not found due to a technical error.
proven by further repeating the experiments.

This can only be

T

R

It

La

Sm RNP Ro tRNl
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Figure 1. Polyacrylamide gel electrophoresis of
P-labeled
nucleic acids from HeLa cells.
Total cell sonicate (lane
T). Bands In other lanes were obtained by immunopreclpitatlon of cell extracts with patient antl-rRNA (lane R)»
normal human serum (lane N), patient antl-La (lane La),
patient antl-Sm (lane Sm), patient antl-RNP (lane RNP),
patient anti-Ro (lane Ro), and patient antl-tRNA (lane
tRNA). The bands labeled 5.8S and 5S are characteristic of
rRNA. See text for the description of other bands.

.

Figure 1
From Lerner, E.A., Lerner, M.R., Hardin, J.A.,
Janeway, C.A. Jr., and Steitz, J.A.
Deciphering the mysteries of RNAcontaining lupus antigens. Arthritis Rheum. 25:761-766, 1982.
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%

Antibody
Specificity

dsDNA
ssDNA
Histones
Sm
RNP
La
Ro
PcNA

.

Frequency

SLE

MCTD

50-60
50-60
25-30
25-30
30-40
10-15
30-40
10

5
20-25
5
5
95-100
5
5
5

Table 1
Specificities of ANAs found in SLE and in mixed
connective tissue disease (MCTD).
From Tan, E.M.
Special antibodies
for the study of systemic lupus erythematosus: An analysis. Arthritis
Rheum. 25:753-756, 1982.
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1
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Cryoglobulins

Figure 2.
Diagram of a double immunodiffusion slide.
1% agarose
in PBS was layered 1mm thick on a glass microscope slide.
Six wells
were punched out on both halves of the slide. The center well
contained the antisera and the five surrounding wells contained
cryoglobulins from various patients and controls.
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Urea-Acrylamide Gel

Figure 3. Apparatus used to transfer RNA from a urea-acrylamide
gel to Northern paper.
Transfer is carried out overnight at room
temperature.

Standards

PEG Cuts

C ryog1obu1 ins

Figure 4,
Comparison of PEG cuts to cryoglobulins precipitated
in the cold.
Sera was obtained from three patients: A, B, C.
Control
lane had proteins of MW 94K, 67K, 43K, 30K, and 20K.

i

4 'V i&

Figure 5. Comparison of protein precipitate from 1ml of SLE sera
and 1ml of sera from healthy volunteers. Four patients and four
volunteers were used and proteins were precipitated with PEG.
Control
lane contains proteins of MW 94K, 67K, 43K, 30K and 20K.

HEALTHY CONTROLS

PEG

SLE PATIENTS

CRYO

Table 2.
Above table shows the results of a double
immunodiffusion experiment.
Antisera against C3, C4, C5, fibrinogen,
ceruloplasmin, IgG and whole serum was diffused against cryoglobulins
from eight healthy controls and five SLE patients. Cryoglobulins from
controls A-E were precipitated with PEG while controls F-H were
precipitated in the cold.
All patient sera was precipitated with PEG.

OD

(280 A
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Figure 6.
10-40$ sucrose density gradient of PEG cuts of SLE
serum. Middle peak, centered around fraction 8, represents the immune
complexes.
Gradient was spun at 27K, at 4°C for 18 hours.

^3

Peaks From Sucrose Gradient

Standards

67K

•'

43K
-

2

3^

5

i

Figure 7.
Acrylamide gel of peaks 1, 2, 3, and 4 which are
centered around fractions 2, 8, 18, and 24, respectively, from the 1040^ sucrose density gradient (Figure 6).
Lane 5 contains protein
standards of MW 94K, 67K, 43K, 30K and 20K. Lane 6 contains IgG and
IgM.
As can be seen, peak 2 contains the immune complexes.
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SLE Sera

Controls

RNA
Standards

U1

12

3^56

7

Figure 8.
Autoradiograph of Northern paper visualizes lanes 5,
6, and 7. Lanes 1-4 were to contain snRNA from immune complexes of
four SLE patients.
No RNA was visualizd.
Lanes 5 and 6 contained Sm
and RNP control immune complexes, respectively.
Lane 7 shows
radiolabeled RNA standards.
The fact that lanes 5-7 are visualized
signifies that RNA extraction, electrophoresis, transfer and
hybridization were correctly performed.
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